BRPI0210335B8 - copolímero de blocos, e, composição - Google Patents

copolímero de blocos, e, composição

Info

Publication number
BRPI0210335B8
BRPI0210335B8 BRPI0210335A BR0210335A BRPI0210335B8 BR PI0210335 B8 BRPI0210335 B8 BR PI0210335B8 BR PI0210335 A BRPI0210335 A BR PI0210335A BR 0210335 A BR0210335 A BR 0210335A BR PI0210335 B8 BRPI0210335 B8 BR PI0210335B8
Authority
BR
Brazil
Prior art keywords
block copolymer
composition
drug
provides
biocompatible
Prior art date
Application number
BRPI0210335A
Other languages
English (en)
Other versions
BR0210335A (pt
BR0210335B1 (pt
Inventor
Kong Han-Uk
Choi In-Ja
Seo Min-Hyo
Original Assignee
Samyang Biopharmaceuticals
Samyang Corp
Samyang Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Biopharmaceuticals, Samyang Corp, Samyang Holdings Corp filed Critical Samyang Biopharmaceuticals
Publication of BR0210335A publication Critical patent/BR0210335A/pt
Publication of BR0210335B1 publication Critical patent/BR0210335B1/pt
Publication of BRPI0210335B8 publication Critical patent/BRPI0210335B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"copolímero de blocos, e, composição". a presente invenção fornece um copolímero de blocos anfifílico contendo grupo aniônico, que é biocompatível e biodegradável e, quando usado como um carreador de medicamento para um medicamento catiônico, proporciona várias vantagens, tais como concentração sangüínea aumentada e estabilidade melhorada do medicamento.
BRPI0210335A 2001-06-25 2002-06-05 copolímero de blocos, e, composição BRPI0210335B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2001/36203 2001-06-25
KR1020010036203A KR100566911B1 (ko) 2001-06-25 2001-06-25 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
PCT/KR2002/001074 WO2003000778A1 (en) 2001-06-25 2002-06-05 Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug

Publications (3)

Publication Number Publication Date
BR0210335A BR0210335A (pt) 2004-07-20
BR0210335B1 BR0210335B1 (pt) 2014-06-24
BRPI0210335B8 true BRPI0210335B8 (pt) 2021-05-25

Family

ID=36792807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210335A BRPI0210335B8 (pt) 2001-06-25 2002-06-05 copolímero de blocos, e, composição

Country Status (16)

Country Link
US (1) US6890560B2 (pt)
EP (1) EP1399501B1 (pt)
JP (1) JP4154328B2 (pt)
KR (1) KR100566911B1 (pt)
CN (1) CN1226332C (pt)
AT (1) ATE337357T1 (pt)
AU (1) AU2002303027C1 (pt)
BR (1) BRPI0210335B8 (pt)
CA (1) CA2449244C (pt)
DE (1) DE60214173T2 (pt)
ES (1) ES2269694T3 (pt)
IL (2) IL159166A0 (pt)
MX (1) MXPA03011619A (pt)
NZ (1) NZ530176A (pt)
WO (1) WO2003000778A1 (pt)
ZA (1) ZA200309357B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523544A (ja) * 2000-02-17 2003-08-05 レックスマーク・インターナショナル・インコーポレーテツド 導電性駆動ハブを備えたトナーカートリッジ
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US20050170004A1 (en) * 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US7179867B2 (en) * 2003-11-26 2007-02-20 Industrial Technology Research Institute Thermosensitive biodegradable copolymer
DE602005008589D1 (de) * 2004-05-05 2008-09-11 Firmenich & Cie Biologisch abbaubare pfropfcopolymere
US20060260638A1 (en) * 2005-03-08 2006-11-23 Pejman Fani Method and system for processing substrates with sonic energy that reduces or eliminates damage to semiconductor devices
KR100773470B1 (ko) * 2005-04-25 2007-11-05 김태균 층간 소음 방지를 위한 방음판 구조
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DE602007004955D1 (de) 2006-03-09 2010-04-08 Coloplast As Abbaubare copolymere mit einem hydrophilen block mit verbesserter biokompatibilität für die weichgeweberegeneration
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
KR100918524B1 (ko) * 2007-02-14 2009-09-21 성균관대학교산학협력단 온도 및 피에치 민감성 블록공중합체 고분자 하이드로겔을이용한 주사가능한 약물전달체 및 약물전달방법
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
WO2009078755A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078756A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
KR101764427B1 (ko) * 2008-05-13 2017-08-02 유니버시티 오브 워싱톤 미셀성 어셈블리
US8652506B2 (en) * 2008-06-05 2014-02-18 Boston Scientific Scimed, Inc. Bio-degradable block co-polymers for controlled release
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
WO2010117957A2 (en) 2009-04-06 2010-10-14 Mayo Foundation For Medical Education And Research Methods and materials for delivering molecules
KR101220162B1 (ko) * 2009-07-02 2013-01-14 한양대학교 산학협력단 아르기닌―기제 양친성 펩티드 마이셀
KR101249389B1 (ko) * 2010-10-28 2013-04-03 재단법인대구경북과학기술원 자극반응성 수화젤
KR101685646B1 (ko) * 2010-12-29 2016-12-13 한화케미칼 주식회사 홍합 접착단백질 모방을 통한 나노입자를 수계 매질에 분산시키는 생체적합성 분산 안정화제
KR101230598B1 (ko) 2011-02-28 2013-02-15 부산대학교 산학협력단 페하 응답성을 가지는 히스트딘이 공유결합된 덱스트란과 메톡시폴리에틸렌글리콜 블록공중합체
EP3027221A1 (en) 2013-07-30 2016-06-08 PhaseRx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
US9657059B2 (en) 2013-09-09 2017-05-23 Canimguide Therapeutics Ab Immune system modulators
CA2978617A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
CN105362251B (zh) * 2015-12-14 2019-02-26 四川大学 DOTAP-mPEG-PLA纳米粒及其纳米粒溶液、载药复合物和制备方法和应用
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
US11590080B2 (en) 2017-12-18 2023-02-28 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
US12558308B2 (en) 2017-12-18 2026-02-24 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
EP3727342B1 (en) * 2017-12-18 2022-02-09 C.R. Bard, Inc. Drug-loaded microbead compositions, embolization compositions and associated methods
CN110742903B (zh) * 2019-11-22 2021-06-01 兰州大学 含铑(ⅰ)的聚合物胶束、其制备方法与应用
MX2024001681A (es) 2021-08-05 2024-03-04 Medincell S A Composicion farmaceutica.
WO2023076284A1 (en) * 2021-10-25 2023-05-04 The Secant Group, Llc Polymeric delivery systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3677019D1 (de) 1986-11-21 1991-02-21 Agfa Gevaert Nv Oberflaechenaktives polymer.
US5035972A (en) 1989-10-31 1991-07-30 E. I. Du Pont De Nemours And Company AB diblock copolymers as charge directors for negative electrostatic liquid developer
CA2029631A1 (en) * 1989-11-22 1991-05-23 Kathleen A. Hughes Graft polymers as biodegradable detergent additives
NL9100218A (nl) * 1991-02-07 1992-09-01 Philips Nv Encodeer/decodeer-schakeling, alsmede digitaal video-systeem voorzien van de schakeling.
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
JPH11510837A (ja) 1995-07-28 1999-09-21 フォーカル，インコーポレイテッド 薬物送達のための制御された放出薬剤および組織処置薬剤としての使用のためのマルチブロック生分解性ヒドロゲル
AU726749B2 (en) 1995-08-10 2000-11-16 Kazunori Kataoka Block polymer having functional groups on its both ends
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
AU8067198A (en) * 1997-06-13 1998-12-30 University Of Nebraska Board Of Regents Compositions for delivery of biological agents and methods for the preparation thereof
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
ZA9811377B (en) * 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
US6210717B1 (en) * 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US5939453A (en) 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6715874B1 (en) * 1999-02-08 2004-04-06 Novartis Ag Organic polymers

Also Published As

Publication number Publication date
EP1399501A1 (en) 2004-03-24
BR0210335A (pt) 2004-07-20
KR20030000433A (ko) 2003-01-06
IL159166A0 (en) 2004-06-01
DE60214173T2 (de) 2007-08-23
BR0210335B1 (pt) 2014-06-24
US6890560B2 (en) 2005-05-10
EP1399501A4 (en) 2005-02-16
HK1067950A1 (en) 2005-04-22
CN1226332C (zh) 2005-11-09
WO2003000778A1 (en) 2003-01-03
CA2449244A1 (en) 2003-01-03
US20030017206A1 (en) 2003-01-23
ATE337357T1 (de) 2006-09-15
KR100566911B1 (ko) 2006-04-03
CA2449244C (en) 2007-10-02
JP2004530768A (ja) 2004-10-07
JP4154328B2 (ja) 2008-09-24
EP1399501B1 (en) 2006-08-23
DE60214173D1 (de) 2006-10-05
AU2002303027C1 (en) 2006-06-01
ES2269694T3 (es) 2007-04-01
NZ530176A (en) 2005-06-24
IL159166A (en) 2007-12-03
MXPA03011619A (es) 2004-04-05
AU2002303027B2 (en) 2005-06-09
ZA200309357B (en) 2005-05-25
CN1520437A (zh) 2004-08-11

Similar Documents

Publication Publication Date Title
BRPI0210335B8 (pt) copolímero de blocos, e, composição
MXPA04000317A (es) Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente.
SV1999000096A (es) Calcio (3s) de propilcarbamato tetrahidro 3-furanil (1s,2r)-3-[[(4-aminofenil) sulfonilo] (isobutilo) amino]-1-bencilo-2-+fosfonooxilo ref. pg3508/sv/0
ATE541587T1 (de) Konjugat-additionsreaktionen zur kontrollierten abgabe von pharmazeutisch wirksamen substanzen
DK1343492T3 (da) Behandling af mucositis
CY1105399T1 (el) Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
PE14199A1 (es) Agonistas de 5-ht1f
BR9909110A (pt) Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
BR9912649A (pt) Naftopiranos anelados em c5-c6, suas preparaçõese composições, e matrizes (co) polìmerascontendo-os
BR0316915A (pt) Composição de manocompósito, método para prepará-lo e seu uso
DE60231862D1 (de) Erodierbare polymere zur injektion
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR0212931A (pt) Composição farmacêutica de liberação prolongada contendo metformina
PY990129A (es) Bromhidrato de eletriptan monohidratado
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
ID25478A (id) Agonis 5-ht1f
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
PT1077606E (pt) Processo para a preparacao de uma composicao antimicrobiana
DK1268522T3 (da) LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
BR9813728A (pt) Composição de dispersão molecular com elevada biodisponibilidade
BRPI0416482A (pt) componente sólido de catalisador para a (co) polimerização de etileno, processo para a preparação de um componente sólido, e, catalisador e processo para a (co) polimerização de etileno

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: EM CONSONANCIA COM A RESOLUCAO NO 34 DO CGEN.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SAMYANG HOLDINGS CORPORATION (KR)

B25A Requested transfer of rights approved

Owner name: SAMYANG BIOPHARMACEUTICALS CORPORATION (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/06/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2726 DE 04-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.